Pfizer, Medivation Commence Two Phase 3 Trials Of Dimebon

Published: 03-Nov-2009

To evaluate the potential benefits of dimebon in combination with current standards of Alzheimer’s care

Pfizer and Medivation have reported the initiation of Contact and Constellation, two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer’s disease (AD).

The Contact study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the AD medication worldwide, on neuropsychiatric symptoms and activities of daily living. The Constellation study evaluates primary endpoints the effects of adding dimebon to memantine HCI, another standard of care, on cognition, memory and activities of daily living.

Pierre Tariot, director of the memory disorders center at the Banner Alzheimer’s Institute and study investigator, said: “These studies are intended to evaluate the potential added benefits of dimebon in combination with current standards of Alzheimer’s care.”

Lynn Seely, chief medical officer at Medivation, said: “Pfizer and Medivation are committed to developing dimebon as a treatment that may meaningfully improve the lives of patients across the full spectrum of Alzheimer’s disease severity. The initiation of the CONTACT and CONSTELLATION studies is an important milestone in the broad clinical development of dimebon.”

Tell your friend about this article